Results support the potential of PMN310 to improve outcomes by selectively targeting oligomers and avoiding binding to monomer and plaque …
Test-Controls & Reference Materials for Labs & Test-MakersMISSISSAUGA, Ontario, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX,…
Test-Controls & Reference Materials for Labs & Test-MakersMISSISSAUGA, Ontario, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX,…
The nation's largest pediatric organization creates comprehensive online resource to combat misinformation and empower parents with evidence-based factsPLANTATION, Fla., Dec.…
Burlington, Ontario--(Newsfile Corp. - December 8, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") announced today that it…
Selective Treg modulator gotistobart (BNT316/ONC-392) showed a reduction in the risk of death by more than half compared to standard…
Triple-class exposed patients with three prior lines of therapy in CARTITUDE-1 and CARTITUDE-4 achieved a median PFS of 50.4 months…
Designed with our proprietary AI-Immunology™ platform based on patient sequencing data, EVX-04 targets multiple non-conventional endogenous retrovirus (ERV) tumor antigensEVX-04…
Maxim Group LLC is acting as the exclusive Financial Advisor for the transaction PHILADELPHIA, PA / ACCESS Newswire / December…
NEW YORK, Dec. 05, 2025 (GLOBE NEWSWIRE) -- via BioMedWire: — Soligenix Inc. (NASDAQ: SNGX) today announces its placement in…